You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms

 

Online download statistics by month:

Online download statistics by month: November 2020 to November 2024

AbstractFullPdf
Nov 2020268024
Dec 20203605
Jan 20213305
Feb 20214506
Mar 202181011
Apr 20215008
May 20213309
Jun 2021008
Jul 2021007
Aug 2021008
Sep 20210010
Oct 202188021
Nov 202196021
Dec 2021100010
Jan 202298015
Feb 2022110014
Mar 2022136015
Apr 2022108014
May 2022132012
Jun 202292011
Jul 20229406
Aug 2022130017
Sep 202211809
Oct 20229608
Nov 2022108010
Dec 20226804
Jan 20238405
Feb 20238205
Mar 202311407
Apr 20239009
May 20237407
Jun 202368010
Jul 20233807
Aug 20234807
Sep 20236605
Oct 20237005
Nov 20236206
Dec 20236605
Jan 20243000
Feb 20243402
Mar 20245602
Apr 20244806
May 20243806
Jun 20246001
Jul 20244402
Aug 20243805
Sep 20245804
Oct 20246605
Nov 20247806
Total35320405